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We  developed a computer program for use in undergraduate and graduate courses in phar-
macology, pharmacokinetics and pharmacodynamics. This program can also be used in
environmental and toxicological studies and preclinical simulation, to facilitate communi-
cation between modeling pharmacokineticists and project leaders or other decision-makers
in  the pharmaceutical industry. The program simulates the drug delivery and transport by
means of (I) a six-compartment physiological pharmacokinetic ﬂow model, (II) a system
of  traditional compartment models, or (III) a target-mediated drug disposition system. The
program also can be used to simulate instantaneous equilibria between concentration and
pharmacodynamic response, or as temporal delays between concentration and response.
The  latter is done by means of turnover models (indirect response models). Drug absorption,
distribution, and elimination are represented by differential equations, which are described
by  organ and tissue volumes or other volumes of distribution, blood ﬂows, clearance terms,
and tissue-to-blood partition coefﬁcients. The user can control and adjust these parameters
by  means of a slider in real time. By interactively changing the parameter values and simul-
taneously displaying the resulting concentration–time and/or response–time proﬁles, users
can  understand the major mechanisms that govern the disposition or the pharmacological
response of the drug in the organism in real time. Schedule dependence is typically seen in
clinical practice with a non-linear concentration–response relationship, and is difﬁcult tocommunicate except via simulations. Here, we sought to illustrate the potential advantagesof  this approach in teachi
undergraduate pharmacy
discovery/development.
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1.  Introduction
Pharmacokinetics (PKs) and pharmacodynamics (PDs) are
distinct disciplines within the traditional pharmacology cur-
riculum. Whereas pharmacokinetics looks at how the body
handles drugs, pharmacodynamics looks at their effects. Phar-
macokineticists and pharmacologists frequently work more  or
less in isolation of each other, a practice that greatly restricts
the detailed understanding of both known and potentially
novel drugs. Therefore, an important question is whether
teaching students using an approach that deliberately and
systematically integrates the activities of these two disci-
plines will enhance our understanding of drugs, and the
efﬁciency and effectiveness of drug discovery and develop-
ment.
Pharmacokinetic models are used to describe the time-
dependent disposition and absorption of a substance in a
living system. For medical purposes, pharmacokinetics can
be used to estimate optimal drug dosage regimens in dif-
ferent therapeutic situations, and for other chemicals be
used to aid decision-making in the risk evaluation of the
working environment. Until now, three main approaches
have been used to analyze the concentration–time behav-
ior of drugs. The classical approach employs either (I)
a sum of exponentials referred to as empirical models,
or (II) compartment models [1]. Although the empiri-
cal and compartmental models have the advantage of
simplicity and meet the needs of most pharmacokinetic
studies, they do not describe a physiological system with
large tissue-to-tissue concentration differences, the effect
of altered perfusion, membrane resistance or changes in
protein binding. The limitations of these classical phar-
macokinetic models have led to the need for a more
realistic way of modeling, namely, (III) physiological ﬂow
models. The general approach in physiological modeling
is to deﬁne the pharmacokinetic processes by means of
physiologically, anatomically, and biochemically meaning-
ful parameters. Every organ is represented by one or more
compartments where each vascular tissue compartment is
interconnected through the circulatory system as in the body
[2].
In this study, we  used a physiologically sound base to
construct a pharmacokinetic model for use in human clini-
cal simulations as well as for pre-clinical (rat) and veterinary
applications (cat, dog, horse). The computer program, which
we call Maxsim2, simulates the drug delivery and transport by
means of (I) a six-compartment physiologically based pharma-
cokinetic ﬂow model, (II) a system of traditional compartment
models, or (III) a target-mediated drug disposition system [3].
Maxsim2 also can be used to simulate instantaneous equilib-
ria between concentration and pharmacodynamic response,
or as temporal delays between concentration and response.
We also illustrate the potential advantages of this parallel
approach of instantaneous coupling or delay between plasma
concentration and pharmacodynamic response, as outlined
in [4], in teaching undergraduate/graduate pharmacology,
pharmacokinetics, and pharmacodynamics to undergraduate
pharmacy-, veterinary-, and medical students or to project
teams in drug discovery/development. b i o m e d i c i n e 1 1 3 ( 2 0 1 4 ) 815–829
2.  Model  description
2.1.  The  physiologically  based  pharmacokinetic  model
The physiologically based pharmacokinetic model used for
the human clinical simulations is shown in Fig. 1. Models
of the rat, cat, dog and horse are also available for veteri-
nary practice. All model parameters, such as organ volumes,
blood ﬂows, partition coefﬁcients, intrinsic clearance terms,
absorption rate constants, maximum metabolic rates and
their Michaelis–Menten constants, and dosing parameters, are
available for real-time adjustment during simulations.
The model comprises only six compartments, which is
obviously a simpliﬁcation but serves the purpose of illus-
trating the multi-compartment distribution of compounds
in PBPK-modeling. The largest (in volume) compartment,
denoted M below, could be interpreted not only to represent
muscle tissue but also to contain all other non-speciﬁcally
modeled tissue such as adipose, bone marrow, etc.  Plasma pro-
tein binding was not an inherent factor in the present version
of the model. Work is ongoing to incorporate plasma protein
concentrations, afﬁnity parameters, and the total number of
binding sites of drug on the protein. These options will be
released in a future version of the program.
The system of ordinary differential equations governing
the behavior of the physiologically based pharmacokinetic
model in Maxsim2 is shown below
VBr
dCBr(t)
dt
= QBr
(
CB(t) − CBr(t)
KPBr
)
, CBr(0) = 0
VM
dCM(t)
dt
= QM
(
CB(t) − CM(t)
KPM
)
, CM(0) = 0
VG
dCG(t)
dt
=  QG
(
CB(t) − CG(t)
KPG
)
+ fAKAA(t), CG(0) = 0
dA(t)
dt
= −KAA(t) +
∑
i
doral,iı(t − ti), A(0) = 0
VH
dCH(t)
dt
=  QHACB(t) + QG CG(t)
KPG
− (QHA + QG)CH(t)
KPH
−CLH CH(t)
KPH
, CH(0) = 0
VR
dCR(t)
dt
= QR
(
CB(t) − CR(t)
KPR
)
− CLR CR(t)
KPR
, CR(0) = 0
VB
dCB(t)
dt
= −QBr
(
CB(t) − CBr(t)
KPBr
)
− QM
(
CB(t) − CM(t)
KPM
)
−QR
(
CB(t) − CR(t)
KPR
)
− (QHA + QG)
(
CB(t) − CH(t)
KPH
)
+dinf (t) +
∑
i
div,iı(t − ti), CB(0) = 0
(1)
where Vind denotes volumes, Cind is concentrations, Qind is
ﬂows, KPind is blood–tissue-partition coefﬁcients, fA is fraction
absorbed, KA is ﬁrst-order absorption-rate constant for drug
from the GI tract to plasma, A is amount of drug in the gut, and
CLind is clearance, respectively. Here ind denotes an index iden-
tifying the corresponding tissue, where Br denotes the brain,
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Fig. 1 – Examples of physiologically based pharmacokinetic model schemes used in Maxsim2, covering models of interest
for drug development and pharmaceutical applications such as models for human and rat and in veterinary practice such
as models for rat, cat, dog, and horse. The Vi denotes organ volumes, Qi blood ﬂows, KPi partition coefﬁcients, CLiH intrinsic
clearance terms, Ka absorption rate constants, Vmax maximum metabolic rates and Km Michaelis–Menten constants, which
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dA(t)
dt
= −KAA(t) +
i
dev,iı(t − ti), A(0) = 0re all available for real time adjustments. For a detailed des
 is muscle, G is gut, H is the liver, HA is the liver (arterial), R
s the kidneys, and B is the blood, respectively. Furthermore,
doral,i =
Doral,i
Mw
dinf =
Dinf
Mw
div,i =
Div,i
Mw
(2)
here Mw is the molecular weight of the compound and Doral,i
nd Div,i are given as amount in grams of compound and Dinf
s given as amount in grams per time unit. There is also an
ption to select nonlinear hepatic clearance in which case CLH
s changed from being a parameter to be a function of CH and
wo new parameters maximum metabolic rate Vmax and the
ichaelis–Menten constant Km, i.e.,  CLH = Vmax/(Km + CH).
.2.  One-compartment  model
 schematic diagram of a traditional one-compartment model
s shown in Fig. 2.
The differential equation for the one-compartment model
n Maxsim2 is
dC(t)
dt
= In(t)  − Cl C(t), C(0) = 0 (3)tion of the nomenclature see the glossary list.
where V denotes volume of distribution, C is the drug con-
centration, and Cl is the plasma clearance. The input term
In(t) constitutes of three parts given by infusion rate, i.v. bolus
doses, and rate of uptake for extravascular administration,
respectively,
In(t) = dinf (t) +
∑
i
div,iı(t − ti) + fAKAA(t)
∑ (4)Fig. 2 – The one-compartment disposition model scheme
used in Maxsim2. For a detailed description of the
nomenclature see the glossary list.
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Fig. 3 – The two-compartment disposition model scheme
used in Maxsim2. For a detailed description of the
nomenclature see the glossary list.
where Imax, IC50 and n denote the efﬁcacy parameter, potency
and sigmoidicity factor, respectively. Models for capturing
temporal differences between plasma concentration and
response are primarily turnover-driven. Delays limited bywhere the lower case ds are deﬁned as above and the differ-
ential equation governs the elimination of an extravascular
(e.g., oral) administrated drug. There is also an option to select
nonlinear clearance, in which case Cl is changed from being a
parameter to be a function of C and two new parameters, max-
imum metabolic rate Vmax and the Michaelis–Menten constant
Km, i.e.,  Cl = Vmax/(Km + C(t)).
2.3.  Two-compartment  model
A schematic diagram of a traditional two-compartment model
is shown in Fig. 3.
The system of differential equations for the two-
compartment model in Maxsim2 is
VP
dCP(t)
dt
= In(t) − ClPCP(t) + CldCT(t) − CldCP(t), CP(0) = 0
VT
dCT(t)
dt
= −CldCT(t) + CldCP(t), CT(0) = 0
(5)
where VP and VT denote plasma volume and tissue volume,
respectively, CP and CT are the drug concentration in plasma
and tissue, respectively, ClP is the plasma clearance, and Cld
is the distributional clearance. The input term In(t) is deﬁned
as in Eq. (4) and in case of nonlinear plasma clearance ClP
is changed from being a parameter to be a function of CP
and two parameters maximum metabolic rate Vmax and the
Michaelis–Menten constant Km, i.e.,  ClP = Vmax/(Km + CP(t)).
2.4.  Target  mediated  drug  disposition  model
Target mediated drug disposition (TMDD) is also an option in
Maxsim2 as shown in Fig. 4. The present version is applicable
to a circulating target R available for reaction with the ligand
L via a second order reaction. b i o m e d i c i n e 1 1 3 ( 2 0 1 4 ) 815–829
The system of ordinary differential equations governing
the behavior of the target mediated drug disposition in
Maxsim2 is
VC
dCL(t)
dt
= In(t) − ClLCL(t) + CldCT(t) − CldCL(t)
−konVCCL(t)CR(t) + koff VCCRL(t), CL(0) = 0
VT
dCT(t)
dt
= −CldCT(t) + CldCL(t), CT(0) = 0
dCR(t)
dt
= ksyn − kdegCR(t) − konCL(t)CR(t)
+koff CRL(t), CR(0) = R0
dCRL(t)
dt
= konCL(t)CR(t) − (koff − ke(RL))CRL(t), CRL(0) = 0
dA(t)
dt
= −KAA(t) +
∑
i
doral,iı(t − ti), A(0) = 0
(6)
where CL denotes the ligand concentration, CT is the sec-
ondary tissue concentration, CR is the target concentration,
CRL is the receptor–ligand complex concentration, and A is the
amount of extravascular drug. The parameters are the central
compartment volume, VC, the secondary tissue compartment
volume, VT, ligand clearance, ClL, distributional clearance, Cld,
receptor–ligand complex second-order on-rate constant and
ﬁrst-order off-rate constant, kon and koff, respectively, basal
zero-order receptor (target) synthesis rate, ksyn, ﬁrst-order
receptor–ligand complex elimination rate constant, ke(RL), ﬁrst-
order absorption rate constant from the GI tract to plasma,
KA, and fraction absorbed, fA. The input term In(t) constitutes
three parts given by infusion rate, i.v. bolus doses, and rate of
uptake for extravascular administration, respectively
In(t) = dinf (t) +
∑
i
div,iı(t − ti) + fAKAA(t) (7)
Furthermore, ksyn is not considered an independent parameter
for manipulation (i.e., it is not available in the menu for param-
eters to be adjusted in Maxsim2), but is in turn parameterized
according to ksyn = R0kdeg, i.e.,  changing R0 or kdeg implies a
change in ksyn.
2.5.  Pharmacodynamic  models
Maxsim2 implements both instantaneous and turnover-
driven (indirect pharmacodynamic) response models. The
instantaneous response models are the ordinary Emax model
with a baseline parameter E0
R = E0 + EmaxC
n
ECn50 + Cn
(8)
where EC50 and n denote the potency and sigmoidicity factor,
respectively. The inhibitory Imax model
R = E0 − ImaxC
n
ICn50 + Cn
(9)
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Fig. 4 – (Top) Schematic illustration of the compartmental
system with the target-mediated drug disposition model
attached. The two-compartment disposition model with
unspeciﬁc binding (CT , VT , Cld) collapses into a
one-compartment model when the inter-compartmental
distribution term is set to zero. Input to the central
compartment can be done via bolus administration,
zero-order constant rate infusion or ﬁrst-order absorption
(KA). (Bottom) The TMDD system is activated when the
target baseline concentration R0 is set to a value greater
than zero. Ligand (L) and target (R) react via a second-order
rate process (kon) resulting in the formation of a
ligand–target complex (RL). The latter can then be degraded
back into L and R or irreversibly lost via ke(RL). The turnover
of the circulating target occurs by means of a zero-order
production (turnover rate R ·kdeg) and ﬁrst-order loss (kdeg).
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ror a detailed description of the nomenclature see the
lossary list.
eceptor-binding on/off rates are captured and can be sim-
lated by the TMDD system (Fig. 4). The turnover (indirect)
esponse models are inhibition of production
dR(t)
dt
= kinI(C) − koutR(t), R(0) = R0
I(C) = 1 − ImaxC
n
ICn50 + Cn
(10) o m e d i c i n e 1 1 3 ( 2 0 1 4 ) 815–829 819
inhibition of the loss term
dR(t)
dt
= kin − koutI(C)R(t), R(0) = R0
I(C) = 1 − ImaxC
n
ICn50 + Cn
(11)
stimulation of the production term
dR(t)
dt
= kinS(C) − koutR(t), R(0) = R0
S(C) = 1 + SmaxC
n
SCn50 + Cn
(12)
and stimulation of the loss term
dR(t)
dt
= kin − koutS(C)R(t), R(0) = R0
S(C) = 1 + SmaxC
n
SCn50 + Cn
(13)
2.6.  Software  design  and  numerical  algorithms
The current version of the program (version 2.0,
www.maxsim2.com) is written in C++ using external
libraries and routines such as wxWidgets, CVODE, and
Boost. The wxWidgets library provides tools for designing
and implementing the graphical user interface of Maxsim2
(http://www.wxwidgets.org) and CVODE is a well-recognized
numerical solver for stiff and non-stiff ordinary differential
equations developed at the Lawrence Livermore National
Laboratory (http://computation.llnl.gov/casc/sundials). Boost
provides high-level platform-independent C++ libraries
facilitating programming productivity and maintenance
(http://www.boost.org). The source code for Maxsim2 is
written for cross platform deployment. The current version
is available for Windows XP and higher and for Mac  OS
X. The pharmacokinetic and pharmacodynamics models
implemented in Maxsim2 and the program’s capability to
accurately compute corresponding numerical solutions for
different dosing regimens have been successfully validated by
comparing simulation results with independent implementa-
tions of these models and their simulations in Mathematica
(http://www.wolfram.com).
3.  Applications  of  Maxsim2  in
undergraduate  teaching
The Maxsim2 program has been frequently used over the
past two years to teach pharmacy students, and in a course
in pharmacokinetics in the medical, toxicological and veteri-
nary curriculum at our institutions. Generally the program is
introduced during the ﬁrst course week, when each student
gets the computer lab instructions and program. A mid-course
question and answer session is followed by a mandatory sum-
mary  session at the end of the course. This saves the teacher’s
time and gives the student a more  ﬂexible working environ-
ment. All students also have to submit a written report before
the ﬁnal examination. We think that the introduction of inter-
active simulation, facilitating the mix  of theory and practice,
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has been very rewarding in terms of improvement of the stu-
dent’s ability to learn and understand new concepts as noted
by several others [5–9].
The following are several examples of assigned concep-
tual exercises regarding the interplay between physiology
and pharmacokinetics, or more  clinically oriented tasks of
maintaining therapeutic drug concentrations in patients and
domestic animals during varying pathological and physiolog-
ical conditions after single or multiple doses.
3.1.  Single  dose  administration
This exercise was divided into three different sections. In the
ﬁrst part, students familiarize themselves with the Maxsim2
program and the type of problems put forward. Students
are then confronted with problems dealing with single i.v.
injection or ﬁrst-order absorption using the human PBPK
model. With the simulator, they can study the impact of
changes in the absorption rate constant, bioavailability (intrin-
sic clearance), and drug interactions, on the blood and tissue
concentration time proﬁles. They are also expected to obtain a
ﬁrm grasp of some of the physiological factors governing the
disposition of a drug during single dose kinetics. Fig. 5 pro-
vides a presentation of the concentration–time plot of drug
in plasma at two different clearance (left) and volume (right)
settings.
3.2.  Oral  and  intravenous  dosing
In this exercise, students demonstrate the impact of a change
in intrinsic hepatic clearance CliH in the human PBPK model
on the plasma concentration–time course after oral and
intravenous infusion regimens, respectively. This simulation
highlights the meaning of the ﬁrst-pass effect and perfusion-
rate (blood ﬂow rate) limited clearance (Fig. 6).
3.3.  Multiple  dosing
The second part of the exercise deals with multiple dosing of
different drugs using the human PBPK model. Currently, we
have compiled data on the pharmacokinetics parameters and
tissue-to-blood partition coefﬁcients of several model drugs:
digoxin, morphine, methadone, theophylline, salicylic acid,
pethidine, and aminoglycosides. In this part of the exercise,
the user should be able to develop a dosage regimen from
knowledge of the pharmacokinetics of the drug and evaluate a
dosage regimen, e.g., ordinary tablet or prolonged-release for-
mulation, from a pharmacokinetic point of view. The aim is
also to make the student familiar with how a change in either
of the absorption rate constant KA, the bioavailability F or fa,
the clearance CI,  or the tissue-to-blood partition coefﬁcient Kp,i
affect the concentration time course during steady state.
An example of a simulation can be seen in Fig. 7, where
a patient receives several doses of theophylline. The stu-
dent can study the impact of a sustained-release dosage form
(absorption rate constant KA small) given to an asthmatic
patient, which is represented by the less ﬂuctuating curve.
When the absorption becomes the rate-limiting step for the
plasma kinetics it also impacts the time to steady-state (lower
simulation in Fig. 7 with KA < 0.05 h−1). Although the time b i o m e d i c i n e 1 1 3 ( 2 0 1 4 ) 815–829
to steady-state is prolonged, the average concentration at
steady-state is still the same.
The user may also simulate a scenario with variable dosing
intervals, in this case a drug given twice a day, at 8:00 A.M. and
2:00 P.M. (Fig. 8).
3.4.  Physiologically  based  pharmacokinetic  (PBPK)
models  and  its  advantage  in  teaching  situations
The goal of the PBPK option is to integrate physiological princi-
ples and pharmacokinetic concepts. To achieve this goal each
pharmacokinetic parameter, e.g., clearance or volume of dis-
tribution, is now treated as a variable instead of as a constant.
The user studies the impact of changes in the tissue-to-blood
partition coefﬁcients, organ blood ﬂows, organ volumes and
clearances, on the time-course of drug in the body. Changes
in tissue (brain, gut, renal, hepatic and skeletal muscle tissue)
uptake and organ blood ﬂows are of particular interest in mak-
ing the user conﬁdent with factors that govern either the time
to reach steady-state, or the drug concentration level in blood
or tissues at equilibrium.
Physiologically based pharmacokinetic models might be
useful in both pharmacology and toxicology to address ques-
tions such as: to what extent is a particular region or organ
exposed to a speciﬁc drug during a given dosing schedule? Can
the obtained concentration–time proﬁle provide any clues to
toxicological effects? or How does multiple dosing inﬂuence
the time course of exposure to chemicals in different tissues
or organs?
3.5.  Target-mediated  drug  disposition
Target-mediated drug disposition is covered in a series of lec-
tures in a pharmacokinetics course followed by a full day
computer lab. One of the introductory exercises is to study
and describe the impact of an increase in dose of the ligand
(e.g., antibody) concentration–time course in plasma (Fig. 9). In
Fig. 10 we illustrate the impact of a change in the target level
expression, R0, on the concentration–time course of ligand
(antibody).
3.6.  Veterinary  application:  theophylline
pharmacokinetics  in  cat  and  horse
In this example, the student has to consider the phar-
macokinetic parameters deciding the average steady-state
concentration and the time to reach steady state by means
of a PBPK model of each species. A horse is being treated with
theophylline 5 mg  kg−1 BID for recurrent airway obstruction.
The therapeutic window is narrow and the half-life in horses
(about 18 h) is more  than twice the half-life in cats (about 8 h).
The dose per kg body weight is the same in cats and horses.
The veterinarian thinks the horse might be overdosed. The
questions the student must answer are what may have caused
this reﬂection? Is it appropriate to give the same dose per kg to
a horse and a cat (given the therapeutic window in plasma)?This exercise compares the concentration–time course fol-
lowing repeated doses of theophylline in a cat of 4 kg and in a
horse of 500 kg body weight. Theophylline is a xanthine deriva-
tive and has a variety of pharmacological effects, including
c o m p u t e r m e t h o d s a n d p r o g r a m s i n b i o m e d i c i n e 1 1 3 ( 2 0 1 4 ) 815–829 821
Fig. 5 – (Left) Semi-logarithmic plot of the plasma concentration–time course of test compound X in the human PBPK model
after an i.v. bolus dose in two  different individuals with different clearance values. Note that the compound displays
one-compartment kinetics (mono-exponential decline) and that the half-life is shorter in the subject with higher clearance.
The area-under-the concentration time curve AUC is also lower when clearance is higher. (Right) Semi-logarithmic plot of
the concentration–time course of test compound X after an i.v. bolus dose in two different individuals with different volumes
of distribution. The area-under-the concentration time curve AUC is equal in the two subjects since clearance is unaffected.
D
r
a
m
a
t
r
F
b
(
c
i
c
w
c
i
tata taken from case study PK1 in [1].
elaxation of bronchial smooth muscles. The most important
dverse effect is cardiac stimulation with resulting arrhyth-
ias. In veterinary medicine, theophylline is especially used
s a bronchodilating drug. In cats, theophylline might be used
o treat asthma. In horses, the drug has been used to treat
ecurrent airway obstruction (RAO). The simulated dose is
ig. 6 – Simulation 1: Semi-logarithmic plot of the concentration–
y a 5 h constant rate i.v. infusion dose starting at 4 h. Note that 
two-exponential decline) after the constant rate infusion using a
oncentration range as the steady-state concentration upon i.v. d
n parallel. Simulation 2: Increase in hepatic intrinsic clearance. 
learance increases due to the ﬁrst-pass effect observed after ora
hich the plasma concentration lowers until it reaches perfusion
learance). Simulation 3: Decrease in hepatic intrinsic clearance. 
ntrinsic clearance decreases. The terminal half-lives increase an
o the maximum plasma concentration tmax after oral dosing inc5 mg  kg−1 twice daily for 9 days both for the cat and the horse.
The oral bioavailability is high and similar in both species.
The simulated plasma concentration–time courses in horse
and cat are shown in Fig. 11. Students assess the mean con-
centration at steady-state, the time to reach steady state,
the parameter(s) that determines the average steady-state
time course of test compound X after an oral dose followed
the compound displays multi-compartment kinetics
 PBPK model. The peak of the oral curve occurs in the same
osing. The terminal half-lives after oral and i.v. dosing fall
The area under the oral curve decreases as hepatic intrinsic
l dosing. This is not seen after intravenous dosing, in
-rate-limited elimination (hepatic blood ﬂow-rate limited
The area under the oral and i.v. curves increases as hepatic
d fall in parallel. The time to steady-state tss and the time
rease.
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Fig. 7 – Concentration–time course of test compound X after three oral formulations. The curve with the fastest absorption
displays the highest ﬂuctuation. When the absorption-rate constant KA is decreased the ﬂuctuations between peak and
trough decrease. When KA is decreased further so absorption becomes the rate-limiting step, then the time to steady-state
is governed by the absorption rate. Still the average concentration at steady-state is the same. A PBPK disposition model
was used.
concentration, and the time to reach steady state. They are
also asked which primary pharmacokinetic parameter(s) dif-
fer between horse and cat (as the half-life differs) based on a
per kg body weight scale.
3.7.  Veterinary  application:  nimesulide  hypothermia  in
dogs –  schedule  dependence
In this exercise, students are asked to design a dosage reg-
imen that lowers the exposure to the drug but still keeps
Fig. 8 – Simulation of the time-course of compound X with an 8 
used.the response at an acceptable level without too much ﬂuc-
tuation in the hypothermic response. Fig. 12 contains two
simulations suggested in Toutain et al. [10]. Each regimen pro-
vides the same total plasma exposure (same total dose). If the
total hypothermic response is summed up, the area under
the response–time course of 2.5 mg  bid is greater and the
hypothermic response contains fewer ﬂuctuations than the
once daily dose of 5 mg.  The ﬁgure shows that the once daily
5 mg  dose causes less hypothermia per day than does 2.5 mg
bid. The drug response is dependent on the dose schedule.
and 16 h dosing interval. A PBPK disposition model was
c o m p u t e r m e t h o d s a n d p r o g r a m s i n b i o m e d i c i n e 1 1 3 ( 2 0 1 4 ) 815–829 823
Fig. 9 – Impact of a change in the dose-slider on the concentration–time course of ligand (antibody) at four different dose
levels. Note how the disposition of ligand displays a complicated multi-phasic concentration–time course at the different
dose levels. The upper curve displays an initially rapid drop (within 1 h (A) shown for the highest and lowest doses)
followed by a slower decline due to distribution (phase B). Phase C is primarily linear elimination and phase D represents
the target mediated disposition. Phase E is the terminal linear phase governed by elimination of the ligand–target complex.
Note how the initial phase A increases as the ligand dose decreases. Phase A is due to the second-order reaction between
ligand and target. Unspeciﬁc binding is represented by a peripheral compartment attached to the central ligand
compartment via a ﬁrst-order process (Fig. 4, top).
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lFig. 13 shows three simulations based on temperature
ata in three individual dogs where only the EC50 value
as been changed and the consequences that has on the
ypothermic time course. Again the students are asked to
xplain why the three simulated curves differ so much and
ow can this be tackled in a population. Students are also
equested to draw the relationship between target concen-
ration range (what concentration is required for a certain
arget effect) and the pharmacodynamic determinants of
hat target range, such as potency, efﬁcacy and the sig-
oidicity factor. This gives a better understanding of how
nter-individual pharmacodynamics differences impact the
arget effect and how potency affects the intensity, and
n particular, the duration of response. Another task is
o draw the corresponding concentration–response relation-
hips provided potency is the only difference between the
ubjects.
.8.  Pharmacological  application:  clinical  signiﬁcance
f potency  differences-schedule  dependence
his exercise tries to elucidate the complexity within the
uestions of potency and powerfulness. In addition to the
axsim2-tasks, the students are expected to construct two
rdinary concentration–response curves out of the peak
esponses obtained during the exercise – one for the drug with
ow efﬁcacy and one for that with high efﬁcacy (full agonist).The assumption is that there is a rapid equilibrium between
plasma concentration and the diuretic effect.
How efﬁciently a diuretic exerts its effect is greatly inﬂu-
enced by the condition of the kidneys, in that the individual
dosage regimen may diverge. The dose is also inﬂuenced
by the variation of the duration of drug effect. In this exer-
cise, a patient is treated with two different diuretics (A and
B), which are considered to be powerful. However, the dos-
ing regimen does not seem to have any effect and a tenfold
increase of the dose is given (10–100 mg). The pharmacoki-
netic parameters are the same for Drugs A and B, which
means that the plasma exposure proﬁles of the two com-
pounds are similar. The system parameters kin and kout are
assumed to be the same for the drugs. Drug A gives a max-
imal drug-induced (Emax) response of 4 arbitrary units (au),
with an EC50 of 7 and an n (Hill coefﬁcient) of 0.4. The corre-
sponding parameters for drug B are 10 au (Emax), 12 (EC50) and
2.7 (n), respectively. The result of the exercise is presented in
Fig. 14.
The student is expected to reﬂect about potency (EC50)
and maximum effect, steepness of response-curve and con-
sequences when increasing the dose to a patient, and also
about what the Hill coefﬁcient actually means. By examining
peak responses to doses other than 10 and 100 mg,  the student
should eventually construct concentration (dose)–response
curves (for drug A and B). If correctly done, the student should
from the curves get the same maximum, EC50 and n values as
presented originally.
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Fig. 10 – Impact of a change in the target level expression (R0) on the concentration–time course of ligand (antibody) at two
different target levels. Note how the disposition of ligand (red curve) displays a complicated multi-phasic
concentration–time course at the different dose levels. The upper red curve displays an initially rapid drop (within 1 h (A)
shown for the highest and lowest doses) followed by a slower decline due to distribution (phase B). Phase C is primarily
linear elimination and phase D represents the target mediated disposition. Phase E is the terminal linear phase governed by
elimination of the ligand–target complex and will not be affected by target expression. Unspeciﬁc binding is represented by
a peripheral compartment attached to the central Ligand compartment via a ﬁrst-order process (Fig. 4, top). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 11 – Semi-logarithmic plot of the concentration–time course of theophylline in cat and horse plasma after repeated oral
doses of 5 mg/kg. Note that the average concentration is similar but the half-lives differ, which also impacts the time to
steady-state. PBPK disposition models for cat and horse were  used.
Data on theophylline are taken from Riviere and Papich [13].
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Fig. 12 – Linear (right hand axis) plot of the response–time course of body temperature in dogs after repeated oral doses of
5 mg  kg−1 24 h−1 and 2.5 mg  kg−1 12 h−1. Data were simulated from mean parameters obtained from eight dogs. Visual
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inspection of the simulations suggests superiority of the 2.5
he underlying kinetic and dynamic model structures see To
.9.  Pharmacological  application:  clinical  signiﬁcance
f potency  differences
ost students easily grasp the deﬁnition of the EC50 value, but
n many  examples that a student may encounter, either from
ublished studies or in teaching exercises, much focus is put
n drug potency and its correlation to the EC50 value, without
ig. 13 – Linear (right hand axis) plot of the response–time cours
.5 mg  kg−1 12 h−1. Data were simulated from low potency value 
og population (EC50 = 2.72 mg  L−1, middle curve) and a high pote
nspection of the simulations demonstrates the impact of a chang−1 12 h−1 dosage regimen. For a detailed description of
n et al. [10].
considering drug efﬁcacy. When they later learn about the con-
cept of partial and full agonists, some students reﬂect over the
validity of EC50 as a pure and simple parameter for describ-
ing potency. This exercise tries to elucidate the complexity
within the questions of potency and efﬁcacy. In addition to
the Maxsim2-tasks, the students are expected to construct
two ordinary dose–response curves out of the peak responses
e of body temperature in dogs after repeated oral doses of
(EC50 = 3.96 mg L−1, upper curve), mean potency in the eight
ncy value (EC50 = 0.50 mg  L−1, bottom curve). Visual
ge with respect to intensity and duration of response [10].
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Fig. 14 – Semi-logarithmic plot of the concentration–time course (red line) and linear plot of response–time (blue line:
excretion of sodium ions in urine) of two diuretics (a, b) after two repeated doses of 10 mg  and two successive doses given of
ber 
e leg100 mg.  The evaluation of the maximum responses to a num
(c). (For interpretation of the references to colour in this ﬁgur
obtained during the exercise – one for the drug with low efﬁ-
cacy and one for that with high efﬁcacy (‘the full agonist’).
In this case, two agonists are evaluated according to sec-
retagogic pancreatic potency; e.g., pilocarpine and carbachol.
A dose–response assessment is performed (10–2000 mg). The
pharmacokinetic parameters are very much the same for drug
A and B. The system parameters kin and kout are considered to
be the same for the drugs. Drug A gives a maximal response
of 2 arbitrary units (au) with an EC50 of 50 mg and with a Hill
coefﬁcient of 0.9. The corresponding parameters for drug B are
4 au, 100 mg  and 1.0, respectively
The student is expected to reﬂect about potency (EC50)
and maximum effect, steepness of response-curve, and conse-
quences when increasing the dose to a patient. By examining
peak responses to other doses than 10 and 100 mg,  the stu-
dent should eventually construct dose–response curves (for
drug A and B). If this is done correctly, the curves should yield
different maximum, and ED50 values from those presented
originally (Fig. 15).
3.10.  Clinical  signiﬁcance  of  nonlinear
concentration–response  curves  –  schedule  dependence
Schedule dependence is the result of a nonlinear
concentration–response relationship. Since many  drugs
Fig. 15 – Semi-logarithmic plot of the concentration–time course
excretion of sodium ions in urine) of two secretagogues (a, b) aft
evaluation of the maximum responses to a number of randomly
red dose–response curve relates to the system presented in (a) an
interpretation of the references to colour in this ﬁgure legend, thof randomly chosen doses (D) should result in the curves in
end, the reader is referred to the web version of this article.)
display a saturable effect relationship (Sigmoidal or Hill-type
of relationship), schedule dependence is an important topic
to tackle for an overall understanding of the consequences
on the clinical outcome when designing a dosing regimen.
A good understanding can easily be reached by practicing
simulations. Fig. 16 demonstrates the relationship between
concentration and time, and pharmacological response and
time, when a dose of 120 mg  is given as a single dose or
separated into three dosing occasions (3× 40 mg). In this
case, the integral of the pharmacological response is >50%)
greater with the separated dosing regimen; a typical example
of dose-schedule dependence. The split regimen not only
results in a lower peak-to-trough variability but also an
extended pharmacological utility of the medicine.
4.  Discussion
Computer models have become common and important sup-
portive tools in university courses [5]. The advantages are
apparent. The models are relatively cheap and individu-
ally accessible tools that allow for problematizing of course
contents. The integration of these models with supervision
performed in dialog with the student creates an almost ideal
learning situation [6]. However, technology-based learning
(TBL) has its disadvantages. Examples of drawbacks are that
 (red line) and linear plot of response–time (blue line:
er oral doses of 10, 20, 100, 200, 1000 and 2000 mg. The
 chosen doses should result in the curves in (c), where the
d the blue dose–response curve to the system in (b). (For
e reader is referred to the web version of this article.)
c o m p u t e r m e t h o d s a n d p r o g r a m s i n b i
Fig. 16 – Semi-logarithmic plot of the concentration–time
courses (red curves and left axis) and the corresponding
response–time courses (blue curves and right hand axis)
following a single 120 mg  dose and 3× 40 mg  separated by
4 h. The shaded area is the extra clinical value from
splitting the 120 mg  into three separated doses –
dose–schedule dependence. (For interpretation of the
references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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netic and pharmacodynamic parameters and variables. Theata taken from Wright et al. [12].
ome students still have low computer literacy and that
tudents may become frustrated by course material and tech-
ology, resulting in less engagement. Students’ appreciation
f TBL has been noted to decrease for several reasons, one of
hich is the course leader’s ignorance of software.
We  believe Maxsim2 addresses many  of these drawbacks by
ts ﬂexibility. The user-friendly software can be maneuvered
t easily accessible levels, as well as at more  advanced ones. In
ddition, since Maxsim2 can address problems at varying lev-
ls, it is less likely to cause student attrition. The simplicity of
he program commands likely overcomes another pedagogic
ssue as well, which is that students often focus on succee-
ing in handling the software package and do not reﬂect on
he meaning of the results. To succeed in understanding the
eaning of results it is important to analyze the different com-
onents of a task and how they are synthetized by giving the
tudent reinforcing feedback in a well-structured manner so
hat ability and knowledge of the learner develops in accor-
ance with course goals [8]. Maxsim2 integrates detailed tasks
ith reﬂecting information, which leads to fewer such prob-
ems. Moreover, students can work in small groups, which
timulate more  thorough theoretical discussions than are pos-
ible during traditional seminars and workshops.
We believe that Maxsim2, centered on real-time interac-
ivity through ‘the slider’ concept, offers several advantages.
he major one is that it gives the student an idea of the phys-
ological determinants that govern the disposition of a drug,
nd also how pharmacokinetic parameters are related to each
ther. Maxsim2 takes this one step further and integrates
xposure with pharmacological responses. It demonstrates o m e d i c i n e 1 1 3 ( 2 0 1 4 ) 815–829 827
more  clearly that target engagement is a conglomerate of
dose, clearance, potency and system properties. This can eas-
ily be studied without equations at the undergraduate level.
By elaborating these models, the student realizes that param-
eters like clearance, volume of distribution, and bioavailability
are variables and not constants, as they are usually regarded.
Furthermore, because it is an interactive program, Maxsim2
gives a quick answer in ‘real time’ to a certain question, rather
than the traditional way of solving a problem by hand calcula-
tor. Experiments that previously have taken days to carry out
in vivo can now easily be simulated in real-time within seconds
and the student instantly observes the impact of a parameter
change on the concentration–time or response–time course(s).
Another important advantage of this type of teaching aid
is that it forces the student to participate more  actively in
problem-solving than the methods commonly used. Students
may also feel that they are ‘in charge of’ drug therapy of the
hypothetical patient, which may motivate them to discuss and
test new alternative methods in drug therapy.
Maxsim2 was written to simulate the impact of different
modes of administration on the disposition of a speciﬁc drug,
and how a change in the physiology affects the pharmacoki-
netics during single and multiple dosing. So far, the students’
response has been that the program saves time and makes
the learning process of pharmacokinetics and pharmacody-
namics more  attractive. The program also allows the user
complete control over design, monitoring, and adjustment of
each dosage regimen. It makes the communication to a small
conference room or a large auditorium easy and direct. The
program is adaptable to many  different situations, for exam-
ple simulating varying dosing intervals, self-administration
of drugs at a certain concentration level, drug interactions,
nonlinearities, and target-mediated drug disposition. Further-
more, the program involves less mathematics to explain a
particular relationship, and the stresses more  of the bio-
logical or physiological approach to pharmacokinetics and
pharmacodynamics. These are important factors since phar-
macokineticists and pharmacologists today are oriented more
toward the physiological approach [11].
In pharmacology courses addressing general principles,
teachers often tend to discuss pharmacological parameters in
an isolated way, rather than in their full context. This ten-
dency may result in lack of a holistic perspective [7]. One
obvious example is when the meaning of an EC50-value is
introduced. The students learn, without actually understand-
ing the meaning of it that this is the agonist concentration
that results in a half maximum response (potency). However,
to fully grasp the signiﬁcance of the parameter, both Emax
(full or partial agonism) and the Hill coefﬁcient need to at
least be considered. Maxsim2 provides excellent opportunities
for students to increase their understanding of the pharma-
cological signiﬁcance of different parameters. By practically
applying the parameters in Maxsim2 models, the importance
for functional effects can be simulated. A further dimen-
sion of the interplay is provided by the Maxsim2-simulated
response being the composite result of both pharmacoki-understanding of the Maxsim2 simulation may be further
elucidated if responses are presented and analyzed in conven-
tional dose–response diagrams. The Maxsim2 software has
 s i n
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the advantage of allowing the user to adapt the exercises to
a suitable level, and the given examples are beneﬁcially pre-
ceded by exercises dealing with just simple demonstrations of,
for instance, the signiﬁcance of differences in potency (varia-
tion of only the EC50 value) or the Hill coefﬁcient (variation of
only n).
Another advantage of the Maxsim2 software is its presenta-
tion of the responses, in which the plasma concentration–time
and the response–time courses will be displayed. This is one
aspect of dose administration that often is neglected in phar-
macology teaching, and it highlights how changes of dosage
regimens actually affect the patient. However, the impact
of some parameters may be more  clearly demonstrated in
traditional dose–response diagrams. This may be plotted sep-
arately, and here the user can see how a large value of the Hill
coefﬁcient compresses the curve. The combination of the two
ways of displaying data, as well as of the user’s hands-on anal-
yses, greatly aids a complete understanding of drug effects
in the body. In this way, Maxsim2 enables student-centered
learning by a phenomenographic approach [9].
Yet another advantage of the Maxsim2 software is that
experiments that earlier have been ethically or practically
difﬁcult to perform in vivo can now easily be carried out in
sequence in a very short time and at a low cost. Work with the
program has generated many  new ideas on further develop-
ment for example modeling drug–drug interactions, modeling
of inter-species scaling and plasma protein interactions. How-
ever, this can only come about with the participation of a
larger group of critical users using the program and gradually
reﬁning and improving its structure.
A fully functional limited-in-time trial version of the soft-
ware  can be downloaded at www.maxsim2.com.
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Glossary
Glossary
A: amount of drug in the GI tract (e.g., mg,  mol)
CL: ligand concentration (e.g., g L−1, mol  L−1)
CP: plasma concentration (e.g., g L−1, mol  L−1)
CR: target concentration (e.g., g L−1, mol  L−1)
CT: peripheral compartment concentration (e.g., g L−1,
mol L−1)
CRL: receptor–ligand complex concentration (e.g., g L−1,
mol  L−1)
Cld: inter-compartmental distribution term (e.g., L min−1,
mL min−1)
ClL: ligand clearance (e.g., L min−1, mL  min−1)
ClP: plasma clearance (e.g., L min−1, mL min−1)
Div: intravenous bolus dose (e.g., mg,  mol)
Dinf: intravenous infusion dose (e.g., mg,  mol)
Doral: oral (extravascular) dose (e.g., mg,  mol)
EC50: potency (e.g., g L−1, mol  L−1)
Emax: efﬁcacy parameter for stimulatory drug action (arbitrary
units)
E0: baseline response (arbitrary units)
fA: fraction absorbed (used as extent of bioavailability for com-
partment models)
GI: gastro-intestinal
IC50: potency (e.g., g L−1, mol  L−1)
Imax: efﬁcacy parameter for inhibitory drug action (arbitrary
units)
In(t): input rate from either a bolus dose, extravascular
administration or constant rate infusion (e.g., g min−1,
mol  min−1)
KA: ﬁrst-order absorption rate constant from the GI tract to
plasma or blood (e.g., min−1, h−1)
kdeg: ﬁrst-order fractional receptor turnover rate constant (e.g.,
min−1, h−1)
ke(RL): ﬁrst-order receptor–ligand complex elimination rate
constant (e.g., min−1, h−1)
Km: Michaelis–Menten constant (e.g., g L−1, mol  L−1)
koff: receptor–ligand complex ﬁrst-order off-rate constant (e.g.,min−1, h−1)
kon: receptor–ligand complex second-order on-rate constant
(e.g., mol  L−1 min−1, g L−1 h−1)
Kpi: tissue-to-blood partition coefﬁcient
i n b i
k
n
P
P
Q
Vi: tissue volume where i denotes brain, GI tract, skeletal mus-c o m p u t e r m e t h o d s a n d p r o g r a m s 
syn: zero-order receptor turnover rate constant (e.g., g min−1,
mol  h−1)
: Hill coefﬁcient also called the sigmoidicity parameter
D: pharmacodynamics
K: pharmacokinetics
i: blood ﬂow where i denotes brain, GI tract, skeletal muscle,
etc. (e.g., L min−1, mL  min−1) o m e d i c i n e 1 1 3 ( 2 0 1 4 ) 815–829 829
R0: target baseline concentration (e.g., g L−1, mol  L−1)
VC: central compartment (e.g., L, mL)cle, etc. (e.g., L, mL)
Vmax: maximum metabolic rate (e.g., g min−1, mol  h−1)
VT: tissue compartment volume (e.g., L, mL)
